Inotropes and vasopressors
Roy S. Gardner, Theresa A. McDonagh, Niki L. Walker
Abstract
Roy S. Gardner, Theresa A. McDonagh, Niki L. Walker
Abstract
Abstract Inotropes are often used to offer haemodynamic support to patients with decompensated heart failure and cardiogenic shock. Although several drugs with inotropic activity are available, it has become increasingly evident that these drugs are associated with important negative effects. The positive inotropic actions of many of these agents are based on increased intracellular calcium concentrations, which may enhance myocardial energy consumption and arrhythmias. This chapter describes the pharmacology and evidence base for the use of inotropes in patients with heart failure.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Abstract Inotropes are often used to offer haemodynamic support to patients with decompensated heart failure and cardiogenic shock. Although several drugs with inotropic activity are available, it has become increasingly evident that these drugs are associated with important negative effects. The positive inotropic actions of many of these agents are based on increased intracellular calcium concentrations, which may enhance myocardial energy consumption and arrhythmias. This chapter describes the pharmacology and evidence base for the use of inotropes in patients with heart failure.
Key concepts: Inotrope, Cardiogenic shock, Heart failure, Shock (circulatory), Medicine, Cardiology, Levosimendan, Internal medicine